Innovative Licensing and Access Pathway (ILAP) - GOV.UK
2025年1月30日 · The ILAP is the only end-to-end access pathway in the world, where the developer can work collaboratively with the national health system, the Regulator, and HTA bodies.
The MHRA Innovative Licensing and Access Pathway is open …
2021年1月1日 · The ILAP combines the MHRA’s globally recognised strengths of independence and high standards of quality, safety, and efficacy, with improved efficiency and flexibility, readying the MHRA for a...
ILAP application guidance - GOV.UK
2025年1月30日 · Following the eligibility review of the application, the ILAP partners (AWTTC, MHRA, NICE, NHS England and SMC) and Lay Members, will jointly consider the application.
The new UK Innovative Licensing and Access Pathway – …
2025年2月4日 · As set out in our previous post, the Innovative Licensing and Access Pathway (ILAP) is an initiative aimed at bringing innovative medicines to the UK market more quickly. On 30 January 2025, the MHRA launched a new version of ILAP in …
MHRA launches refreshed ILAP to speed up NHS drug access
2025年1月30日 · The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has launched a refreshed Innovative Licensing and Access Pathway (ILAP) to accelerate patient access to new medicines by integrating regulatory and health technology assessment procedures.
政府机构 | DBT 生命科学与医疗健康
MHRA 将药品创新许可和获取途径（ILAP）与现有的药品早期获取计划（EAMS）一起运营。MHRA表示, ILAP范围更广，并且对所有创新产品开放。 EAMS则将支持解决未竟医疗需求且接近开发尾声产品的早期患者获药。 MHRA发布的药品创新许可和获取途径旨在加快产品上市时间，促进患者获取创新药物产品，包括新化学实体、生物医学、新适应症或再利用药物。 针对具体特定产品，专家团队将根据产品特征帮助定义“目标开发概况”（TDP）。 TDP 将定义关键监管和开 …
英国药监局公布创新许可途径以加快药品开发 - phirda.com
2020年12月29日 · 英国药品与医疗保健产品监管机构（mhra）发布了有关正在建立的创新许可和获取途径（ilap）的指南，以加快产品上市时间。 这一途径下的药品开发商将收到从 MHRA 及利益相关方（包括英国国家卫生与临床优化研究所）的更多反馈。
Launch of Refreshed Innovative Licensing and Access Pathway (ILAP)
2025年1月31日 · Full details have now been published on the refreshed UK-wide Innovative Licensing and Access Pathway (ILAP), that will offer a clearer, more streamlined and integrated process for developers to help get transformative new clinically and cost-effective medicines to patients in the National Health Service (NHS) in the shortest time possible.
Re-Launch of UK’s Innovative Licensing and Access Pathway (“ILAP”)
2025年2月14日 · The ILAP is an “end-to-end” access pathway offering a unique opportunity for a medicine’s developer to engage with: (i) the UK’s medicines regulator – the Medicines and Healthcare products...
What’s on offer in the ILAP - GOV.UK
2025年1月30日 · Innovation Passport holders receive prioritised scheduling to gain access, at the right time, to a range of services offered by the ILAP partners, such as the Medicines and Healthcare products...